COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TRD) is still nourishing the psychedelics research field, as newly published data demonstrate the therapy’s potential beyond the reduction of depression.
These outcomes point to greater improvement in anxiety, quality of life, positive and negative emotions, cognitive function and ability to take part in everyday tasks as reported by participants who received 25mg psilocybin single doses vs. those who received the 1mg single doses after three weeks. The 10 mg group also self-reported improvements as compared with the 1 mg group, although to a lower degree.
Specifically:
-
The 25 mg dose was associated with an increase in the positive affect score and a decrease in the negative affect score at Week 3 after dosing.
-
The anxiety measure also showed that the 25 mg dose produced greater improvement compared with the 1 mg dose than the 10 mg dose at Week 3.
-
The 25 mg and 10 mg doses also improved measures of function at Week 3.
-
Effects on quality of life and cognitive function were smaller at Week 3.
-
At Week 12, the treatment differences were less pronounced, however maintaining the same dose-dependent trends.
Quick Q&A With COMPASS
The study's findings seem to make the case for psilocybin's multifaceted effect on a set of measures related to TRD, further supporting its development …